Center for Environmental and Health Effects of PFAS

项目摘要/摘要 该项目扩展了由北卡罗来纳州环境和环境研究中心资助的GenX暴露研究 全氟烷基物质(PFAS)对健康的影响，以回答与全氟烷基物质和多氟烷基物质(PFAS)暴露有关的紧急问题 它们对SARS-CoV-2应答的影响。全氟辛烷磺酸作为一类与免疫抑制有关，这在人类中得到了证实 高暴露人群对普通疫苗的抗体滴度较低。利用GenX暴露研究，一项 在对1,000名接触PFAS的个人进行的前瞻性研究中，我们计划回答两个问题：1) 在这个人群中有明显的疾病、症状、后遗症和抗体吗？2)接触全氟辛烷磺酸是否会改变对 用抗体测量的病毒？这项研究位于北卡罗来纳州的恐惧角地区，参与者包括 年龄从8岁到86岁不等，有不同的人口统计和病史。这项研究中的全氟辛烷磺酸水平很高 高于全国测量的全氟辛烷磺酸测定值；在这一人群中，已在血清中检测到新型氟醚 约占血清中PFAS总水平的25%。在这个人群中，我们计划采集两个血液样本 SARS-CoV-2抗体检测，一次在2020年秋季，另一次在2021年夏天。此外，我们还将管理 在这项为期一年的研究中，对五个时间点的与COVID19疾病和症状相关的调查 队列中持续的疾病经历。我们目前预计抗体阳性感染的流行率为10% (2020年6月)；我们预计随着北卡罗来纳州感染率的增加，这一数字将会增加。我们将使用PFAS值 在2020年秋季进行测量，在横断面分析中评估PFAS暴露和SARS-CoV-2反应的影响；我们 将使用相同的PFAS措施，以纵向方式评估这些结果的PFAS风险敞口 在PFAS测量后收集。有1000名参与者，这将是迄今为止规模最大的研究之一 通过抗体测量的全氟辛烷磺酸暴露和免疫反应。鉴于PFAS抑制免疫功能，暴露于 可能会导致更严重的疾病，因为个人没有产生足够的病毒抗体，或者可能导致较轻的疾病 自所谓的“细胞因子风暴”以来的疾病可能会通过较差的免疫反应得到缓解。我们的研究将为我们提供 调查数据与抗体数据和保存的样本相结合，以进一步探讨全氟辛烷磺酸如何影响COVID。如果一个 在我们的研究期间，如果疫苗可用并被采用，我们将把重点转移到疫苗反应上。我们计划工作 与我们的社区合作伙伴，包括当地非政府组织和卫生部门，分享成果 及时与研究参与者和社会各界进行交流。本附录补充了正在进行的研究 北卡罗来纳州超级基金中心，并允许我们利用正在进行的流行病学研究来解决这一重要的公众 健康问题。

Project Summary/Abstract This project expands the GenX Exposure Study funded through the NC State Center for Environmental and Health Effects of PFAS to answer urgent questions related to per-and polyfluoroalkyl substances (PFAS) exposure and their impacts on SARS-CoV-2 response. PFAS as a class are associated with immune suppression as evidenced in humans by lower antibody titers to common vaccines in higher exposed individuals. Using the GenX Exposure Study, a prospective study of 1,000 PFAS exposed individuals, we plan to answer two questions: 1) what is the prevalence of overt disease, symptoms, sequelae, and antibodies in this population? and 2) does PFAS exposure modify response to virus as measured by antibodies? This study, located in the Cape Fear Region of North Carolina, includes participants ranging in age from 8-86 years with diverse demographic and medical histories. PFAS levels in this study are much higher than the national values for PFAS measured; in this population, novel fluoroethers have been measured in serum and represent ~25% of the overall PFAS levels in serum. In this population, we plan to collect two blood samples for SARS-CoV-2 antibody testing, once in the fall of 2020 and again in the summer of 2021. Additionally, we will administer a survey related to COVID 19 disease and symptoms at five points in time during this one-year study to capture the ongoing disease experience of the cohort. We currently anticipate a prevalence of antibody positive infection of 10% (June 2020); we expect this to increase as the rates of infection are increasing in North Carolina. We will use PFAS values measured in Fall 2020 to assess the impact of PFAS exposure and SARS-CoV-2 response in cross-sectional analyses; we will use the same PFAS measures to assess PFAS exposures on these outcomes in a longitudinal fashion for data collected following PFAS measurement. With 1000 participants, this will be one of the largest studies to date regarding PFAS exposure and immune response as measured by antibodies. Given that PFAS suppress immune function, exposure may result in worse disease because individuals fail to make sufficient antibodies to the virus, or may result in milder disease since the so-called “cytokine storm” may be mitigated by poorer immune response. Our study will provide the survey data combined with antibody data and stored specimens to further explore how PFAS influence COVID. If a vaccine becomes available and is adopted during our study, we will shift our focus to vaccine response. We plan to work with our community partners both local non-governmental organizations and health departments to share results with study participants and the community in a timely fashion. This supplement complements the ongoing research at the NC State Superfund Center and allows us to leverage an ongoing epidemiological study to address this important public health issue.